

Regimen Reference Order – BRST – PACLitaxel + trastuzumab

ARIA: BRST – [PACLitaxel + trastuzumab (ADJ)]

Planned Course: PACLitaxel and trastuzumab every week for 12 weeks (1 cycle = 21 days), followed by trastuzumab every 21 days for 14 cycles

Indication for Use: Breast Cancer Adjuvant HER2 positive

CVAD: At Provider’s Discretion

Proceed with treatment if:

Cycles 1 to 4

- *ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$*

Cycles 5 to 18

- *Blood work at provider’s discretion: not required to proceed with treatment*

❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – BRST – PACLitaxel + trastuzumab

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Cycle 1		
Day 1		
trastuzumab (brand name specific)	4 mg/kg Loading Dose	IV in normal saline 250 mL over 90 minutes <i>*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order</i> <i>*Nursing Alert: PACLitaxel infusion begins after observation period is complete</i>
famotidine	40 mg	Orally 1 hour prior to PACLitaxel
cetirizine	10 mg	Orally 1 hour prior to PACLitaxel
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes
Wait 30 minutes after completion of IV pre-medications before starting PACLitaxel		
PACLitaxel	80 mg/m ²	IV in normal saline 250 mL over 1 hour <i>Use non-DEHP bags and non-DEHP administration sets with 0.2</i>

		or 0.22 micron filter
Days 8 and 15		
trastuzumab (brand name specific)	2 mg/kg	IV in normal saline 250 mL over 30 minutes <i>*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order</i>
famotidine	40 mg	Orally 1 hour prior to PACLitaxel
cetirizine	10 mg	Orally 1 hour prior to PACLitaxel
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes
Wait 30 minutes after completion of IV pre-medications before starting PACLitaxel		
PACLitaxel	80 mg/m ²	IV in normal saline 250 mL over 1 hour <i>Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter</i>
Cycles 2 to 4		
Days 1, 8 and 15		
trastuzumab (brand name specific)	2 mg/kg	IV in normal saline 250 mL over 30 minutes <i>*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order</i>
famotidine	40 mg	Orally 1 hour prior to PACLitaxel
cetirizine	10 mg	Orally 1 hour prior to PACLitaxel
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes
Wait 30 minutes after completion of IV pre-medications before starting PACLitaxel		
PACLitaxel	80 mg/m ²	IV in normal saline 250 mL over 1 hour <i>Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter</i>
Cycles 5 to 18		
trastuzumab (brand name specific)	6 mg/kg	IV in normal saline 250 mL over 30 minutes <i>*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order</i>
All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See BRST DSG – Dose Banding document for more information		

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Cardiac monitoring

- Left Ventricular Ejection Fraction (LVEF) monitoring is recommended at baseline and every 4 cycles

Cycle 1

Day 1

- CBC, biochemistry and liver enzymes as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- Observe patient for 30 minutes after administration of trastuzumab. Full vital signs after observation period is complete. PACLitaxel infusion begins after observation period is complete
- No observation period required after PACLitaxel administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Days 8 and 15

- CBC as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period required after trastuzumab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Cycles 2 to 4

Day 1

- CBC, biochemistry and liver enzymes as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period required after trastuzumab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Days 8 and 15

- CBC as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period required after trastuzumab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Cycles 5 to 18

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period required after trastuzumab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Cycles 1 to 4 ONLY – PACLitaxel + trastuzumab		
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

All Cycles

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge

Cycles 1 to 4

- Instruct patient to continue taking anti-emetic(s) at home

- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Reassess trastuzumab dose with significant weight changes
- PACLitaxel may cause progressive, irreversible neuropathy
- trastuzumab is available from more than one manufacturer and uses several different brand names. Brand name will be indicated in brackets after trastuzumab. **Ensure prescription label matches the brand name on prescribed order**
- **Note: At Cycle 4**, an entry called “*Physician Reminder – Order remaining trastuzumab 1 units Insert Miscellaneous Once*” will appear in the electronic drug order. No action is required. **This prompt is to remind the prescriber to order single agent trastuzumab which begins at Cycle 5**
- **Note:** Cycle 5 begins 7 days after Cycle 4, Day 15